Ocugen Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Shankar Musunuri
Chief Executive Officer (CEO)
US$4.8m
Compensación total
| Porcentaje del salario del CEO | 15.65% |
| Permanencia del CEO | 13yrs |
| Participación del CEO | 0.8% |
| Permanencia media de la dirección | 1.2yrs |
| Promedio de permanencia en la Junta Directiva | 5.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Seeking Alpha • Sep 10
Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
Summary Ocugen, Inc. is maintained at a Hold rating due to mixed clinical progress and ongoing pivotal trials across its ophthalmology pipeline. The company's OCU400 gene-agnostic therapy for retinitis pigmentosa shows promise, with phase 3 liMeliGhT top-line data expected in Q1 2027 and strong phase 1/2 results. OCU410ST for Stargardt disease faces uncertainty after a negative interim analysis, but the phase 2/3 GARDian3 trial will continue with full sample assessment. OCGN's cash runway extends into 2028 following a $130M convertible note raise, reducing near-term dilution risk and supporting ongoing R&D. Read the full article on Seeking Alpha
Actualización de narrativa • Aug 16
OCGN: Upcoming Gene Therapy Readouts And RMAT Status May Re Rate Shares
Analysts lifted their Ocugen fair value estimate from $7.00 to $8.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin, and a very large future P/E multiple that reflects the company’s clinical pipeline and upcoming trial milestones. Analyst Commentary Street research coverage on Ocugen remains active, with recent updates giving investors a mix of optimism around the clinical pipeline and a reminder of the risks that come with early stage biotech exposure.Actualización de narrativa • Aug 02
OCGN: Upcoming Gene Therapy Trials And RMAT Pathway Could Re Rate Shares
Ocugen's updated analyst price target has shifted modestly to $11 from $12, with analysts pointing to recent discussions on upcoming clinical milestones and trial preparations as the key reasons for refining their models. Analyst Commentary Recent commentary on Ocugen highlights a mix of interest in the clinical pipeline and caution around how that pipeline translates into long term value.
Actualización de narrativa • Jul 07
OCGN: Upcoming Retinal Trial Readouts Will Shape Future Upside Potential
Analysts raised their fair value estimate for Ocugen to about $20.62 from $15.00, citing updated assumptions for revenue potential, profitability, and a lower expected future P/E multiple based on recent clinical and regulatory progress discussed in recent research. Analyst Commentary Recent Street research on Ocugen shows a mix of optimism around the pipeline and caution around timing and execution, which together help explain the latest fair value revisions.
Actualización de narrativa • Jun 23
OCGN: Gene Therapy Pivotal Trials And 2027 Readouts Will Drive Repricing
Ocugen's analyst price target has shifted modestly, with one firm trimming its view from $12 to $11 while others recently raised their targets by $3 to $4. This reflects analysts' focus on the company's gene therapy pipeline, ongoing pivotal trials and upcoming clinical catalysts.Actualización de narrativa • Jun 05
OCGN: Retinal Gene Therapies Will Gain Momentum With Upcoming 2027 Readouts
Ocugen's analyst price target has edged down by $0.14 to $11.43 as analysts refresh their models around updated expectations for revenue growth, profitability, and long term P/E assumptions following recent gene therapy trial updates and upcoming catalysts across the retinal disease pipeline. Analyst Commentary Recent research updates show a mix of optimism around Ocugen's gene therapy pipeline and some caution on execution risk and timing, which is feeding into the modest reset in the average price target.Actualización de narrativa • Apr 26
OCGN: Retinal Gene Therapy Pipeline Will Drive Future Upside Potential
Narrative Update on Ocugen Analyst price targets for Ocugen have moved higher, with several recent increases of $3 to $7 tied to positive preliminary data for OCU410, expectations around OCU400 in retinitis pigmentosa, and a growing view of the company as an emerging player in gene therapy for blinding ocular disorders. Analyst Commentary Recent research coverage on Ocugen centers on its gene therapy pipeline and the implications for valuation if key clinical and regulatory milestones are met.Actualización de narrativa • Apr 11
OCGN: Late Stage Retinal Gene Therapies Will Drive Future Upside Potential
Ocugen's analyst price targets have moved higher by several dollars, with analysts pointing to Ocugen's Phase 3 OCU400 program, early OCU410 data and a perceived opportunity in retinal disease markets as key reasons for the updated views. Analyst Commentary Recent research coverage on Ocugen has leaned constructive, with several firms updating their models and price targets after new clinical data and program milestones.Actualización de narrativa • Mar 28
OCGN: Retinal Gene Therapy Milestones Will Drive Future Upside Potential
Ocugen's updated fair value estimate has shifted to $11.57 from $10.36 as analysts factor in a series of higher price targets on the stock, supported by recent positive clinical data and new coverage that highlights its gene therapy pipeline in retinal diseases. Analyst Commentary Recent research on Ocugen is clustered around its gene therapy portfolio in retinal diseases, with several firms updating models and targets after new data readouts and coverage initiations.Actualización de narrativa • Mar 12
OCGN: Late Stage Gene Therapy Progress Will Drive Future Upside Potential
Ocugen's analyst price target has moved higher toward $22, reflecting updated fair value estimates of about $10.36 per share and analyst focus on recent OCU410 Phase 2 data and OCU400's Phase 3 progress in blinding ocular disorders. Analyst Commentary Recent research on Ocugen centers on how the new OCU410 Phase 2 readout and the OCU400 Phase 3 program could influence valuation, risk, and execution over the next few years.Actualización de narrativa • Feb 25
OCGN: Trial Progress And CFO Appointment Will Support Future Upside Potential
Narrative update on Ocugen Analysts have made a modest adjustment to their Ocugen price target, keeping fair value around $9.00. Small tweaks to the discount rate and future P/E assumptions refine, rather than overhaul, their view on the stock.Actualización de narrativa • Feb 11
OCGN: Positive Trial Data And New CFO Appointment Will Drive Upside
Ocugen's updated analyst price target edges higher, with a new fair value estimate of $9.00 per share supported by slightly adjusted assumptions for the discount rate, long term revenue growth, profit margin, and future P/E multiple. This indicates analysts are fine tuning their models rather than making a major shift in view.Actualización de narrativa • Jan 27
OCGN: Positive Trial Data And Capital Raise Will Drive Future Upside
Narrative Update The analyst price target for Ocugen has been fine tuned by a few cents, with only marginal shifts in fair value, discount rate, revenue growth, profit margin, and future P/E assumptions as analysts adjust their models in line with recent industry wide recalibrations seen in other coverage. Analyst Commentary Recent Street research on other companies in the broader building products and housing related space shows a mix of optimism on long term demand and caution around nearer term volatility.Actualización de narrativa • Jan 12
OCGN: Pipeline Milestones Will Drive Upside As Execution Risks Moderate
Analysts have trimmed their fair value estimate for Ocugen to $9.00. They link this move to slightly lower assumed discount rates and modest tweaks to long term revenue growth, profit margin, and future P/E expectations.Actualización de narrativa • Dec 15
OCGN: Pipeline Milestones Will Support Upside Despite Competitive And Capital Allocation Risks
Analysts have modestly trimmed their price target on Ocugen to around $9.00 per share. This reflects slightly lower discount rate and valuation assumptions as they factor in sustained but more competitively pressured growth and margins.Actualización de narrativa • Nov 29
OCGN: Exclusive Licensing Deal Will Drive Upside Amid Industry Headwinds
Ocugen's analyst price target remains steady at $9.00, as analysts cite ongoing competitive pressures and a lack of expected demand rebound in the sector as key factors for maintaining their current valuation outlook. Analyst Commentary Analyst sentiment around Ocugen reflects a balance of cautious optimism and ongoing concerns, shaped by sector-wide trends and company-specific challenges.Actualización de narrativa • Nov 15
OCGN: Upbeat Licensing Agreement Is Expected To Drive Shareholder Value In Coming Years
Narrative Update: Ocugen Analyst Price Target Revision Analysts have raised their price target for Ocugen from $8.20 to $9.00, citing increased revenue growth expectations and improved profit margin forecasts. Analyst Commentary Following the recent revision in Ocugen's price target, analysts have provided additional insight into the factors influencing their perspectives.Actualización de narrativa • Nov 01
OCGN: Future Licensing Deals And Regulatory Milestones Will Drive Long-Term Opportunity
Ocugen's analyst price target remained steady at $8.20, as analysts see unchanged fair value amid stable growth projections and profitability outlooks, according to recent reviews. Analyst Commentary Recent Street research provides a mixed outlook for Ocugen, reflecting both positive momentum and ongoing challenges as analysts assess the company's valuation and prospects for future growth.Actualización de narrativa • Oct 17
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target was reaffirmed at $8.20, as analysts cite stable revenue growth and profit margin projections, with only minor changes to discount rate and future P/E assumptions supporting their steady outlook. Analyst Commentary Street research highlights a range of perspectives surrounding Ocugen’s outlook, as analysts weigh factors that could either support or limit future upside in the company’s valuation and execution.Actualización de narrativa • Oct 03
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Ocugen's analyst price target has been raised significantly from $6.48 to $8.20, reflecting growing optimism among analysts based on stronger projected revenue growth and improving profit margins. Analyst Commentary Recent price target revisions signal a shift in analysts' outlook on Ocugen, highlighting both enthusiasm and lingering concerns regarding the company’s path forward.
Nueva narrativa • Apr 02
Gene Therapy Advances Will Unlock New Treatment Options
Advancing gene therapies for unmet needs may drive significant future revenue growth and market share if upcoming products secure approvals.Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$82m |
| Mar 31 2026 | n/a | n/a | -US$72m |
| Dec 31 2025 | US$5m | US$758k | -US$68m |
| Sep 30 2025 | n/a | n/a | -US$64m |
| Jun 30 2025 | n/a | n/a | -US$57m |
| Mar 31 2025 | n/a | n/a | -US$58m |
| Dec 31 2024 | US$2m | US$758k | -US$54m |
| Sep 30 2024 | n/a | n/a | -US$51m |
| Jun 30 2024 | n/a | n/a | -US$50m |
| Mar 31 2024 | n/a | n/a | -US$58m |
| Dec 31 2023 | US$5m | US$758k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$79m |
| Jun 30 2023 | n/a | n/a | -US$90m |
| Mar 31 2023 | n/a | n/a | -US$86m |
| Dec 31 2022 | US$8m | US$715k | -US$87m |
| Sep 30 2022 | n/a | n/a | -US$74m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$8m | US$541k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$500k | -US$34m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$572k | US$420k | -US$20m |
Compensación vs. Mercado: La compensación total de Shankar($USD4.84M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD2.41M).
Compensación vs. Ingresos: La compensación de Shankar ha aumentado mientras la empresa no es rentable.
CEO
Shankar Musunuri (62 yo)
13yrs
Permanencia
US$4,841,822
Compensación
Dr. Shankar Musunuri, Ph D., MBA, is Co-Founder of OrthoCellix, Inc. and serves as its Chairman, Chief Executive Officer President and Secretary. Dr. Musunuri is the Co-Founder of Ocugen, Inc. since Septem...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 13yrs | US$4.84m | 0.84% $ 2.9m | |
| Chief Scientific Officer and Head of Research & Development | 4yrs | US$2.14m | 0.063% $ 220.9k | |
| CFO & Principal Accounting Officer | less than a year | sin datos | 0.15% $ 537.0k | |
| Executive Vice President of Operations | less than a year | sin datos | sin datos | |
| General Counsel | no data | sin datos | sin datos | |
| VP of Corporate Communications | less than a year | sin datos | sin datos | |
| Head of People & Culture | 2.4yrs | sin datos | sin datos | |
| Chief Development Officer | 1.2yrs | US$1.31m | sin datos | |
| Chief Medical Officer | less than a year | sin datos | sin datos | |
| VP & Head of Regulatory & Quality | 3.6yrs | sin datos | sin datos | |
| VP, Head of Program Management & Chief of Staff | 2.7yrs | sin datos | sin datos | |
| Executive Vice President of Commercial and Business Development | 1.2yrs | sin datos | sin datos |
1.2yrs
Permanencia media
55.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de OCGN no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 7yrs | US$4.84m | 0.84% $ 2.9m | |
| Member of Retina Scientific Advisory Board | 6.8yrs | sin datos | sin datos | |
| Member of Retina Scientific Advisory Board | no data | sin datos | sin datos | |
| Vaccine Scientific Advisory Board Member | 5.8yrs | sin datos | sin datos | |
| Co-founder & Independent Director | 7yrs | US$211.25k | 0.21% $ 726.2k | |
| Vaccine Scientific Advisory Board Member | 5.8yrs | sin datos | sin datos | |
| Independent Director | 1.3yrs | US$182.32k | 0% $ 0 | |
| Independent Director | 7yrs | US$196.25k | 0.40% $ 1.4m | |
| Independent Director | 6.4yrs | US$203.75k | 0.022% $ 77.3k | |
| Independent Director | 1.3yrs | US$205.18k | 0% $ 0 | |
| Vaccine Scientific Advisory Board Member | 5.8yrs | sin datos | sin datos | |
| Chair of Retina Scientific Advisory Board | 2.3yrs | sin datos | sin datos |
5.8yrs
Permanencia media
60.5yo
Promedio de edad
Junta con experiencia: La junta directiva de OCGN se considera experimentada (5.8 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/12 20:41 |
| Precio de las acciones al final del día | 2026/09/11 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Ocugen, Inc. está cubierta por 7 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Whitney Ijem | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Elemer Piros | Lucid Capital Markets |